Clinical Trials Logo

Methylene Blue clinical trials

View clinical trials related to Methylene Blue.

Filter by:
  • None
  • Page 1

NCT ID: NCT05830630 Recruiting - Clinical trials for Lower Limb Amputation

Perineural Methylene Blue Infusion in Lower Limb Amputation Surgery

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

This prospective randomized controlled study will be conducted to evaluate the analgesic effect of continuous perineural infusion of methylene blue with bupivacaine on acute postoperative pain and to evaluate its preventive role against chronic phantom pain in patients undergoing lower limb amputation surgery

NCT ID: NCT05113628 Completed - Clinical trials for Recurrent Laryngeal Nerve Injuries

Methylene Blue Spray for Identification of Recurrent Laryngeal Nerve and Parathyroid Gland

Start date: January 15, 2020
Phase: N/A
Study type: Interventional

Thyroidectomy is the procedure by which surgeons treat various thyroid diseases and is considered the commonest endocrinal surgery. Yet, it carries a risk for intraoperative complications. The most distressing complications are recurrent laryngeal nerve and parathyroid injuries. Methylene blue spray is a technique than can be used for easy identification of both recurrent laryngeal nerve and parathyroid glands so we can avoid their injuries.

NCT ID: NCT01725477 Completed - Laparoscopy Clinical Trials

Laparoscopic Tubal Patency Assessment

Start date: September 2012
Phase: N/A
Study type: Interventional

1. Methylene blue in laparoscopy use for tubal patency assessment 2. Methylene blue could have negative effect on sperm motility, oocyte granulosa cell and fertility. 3. tubal washing after Methylene blue administration could be effective in pregnancy rate after operation.

NCT ID: NCT00176072 Completed - Pharmacokinetics Clinical Trials

BlueCQ Bioavailability

Start date: August 2004
Phase: Phase 1
Study type: Observational

Bioavailability of methylene blue (MB) - comparison of an i.v. and two oral MB formulations - and influence of sustained release MB on chloroquine (CQ) concentrations in whole blood, plasma and urine. Intraindividual cross over open comparison in healthy male and female individuals (6:6) with different MB formulations in randomised order for the determination of the absolute bioavailability of MB (part 1), followed by an explorative randomised parallel group comparison of CQ disposition when CQ is given alone (3 males and 3 females) or in combination with 1000 mg sustained release MB (3 males and 3 females) in the participants of study part 1 (part 2).